

expressTEC ®

Next-Generation RNA Companion Diagnostics

www.expresstec.pt

[@expressTEC](https://twitter.com/expressTEC)
[#expressPIK](https://twitter.com/expressPIK)



The Problem

40-50%

cancer patients
do not respond
to the 1st line of therapy



+€100 billion spent

globally on failed approval of
oncology drugs



+ €220 billion spent

globally on cancer treatments



9.74 million lives lost

to cancer in 2022 alone



Our Mission

*We develop accurate and fast cancer
treatment-decision technology
that improve patient outcomes*

DNA testing leads to treatment mismatch and costs lives

False positives
drive the
treatment failure


10-20%
of breast cancer mutations
do not generate RNA

No benefit
Adverse side effects




**Mutant
DNA**

All Current Tests



**Mutant
RNA**



**Mutant
Protein**

Drug Targets

expressTEC[®] |||

1st RNA & AI-based
technology
for targeted
treatment
eligibility



>20% treatment response
than with DNA testing



Quantitative Biomarkers
Prognostic AI Algorithm




Scalable Platform
Many cancers, Many mutations



expressPIK[®] - most common mutations in breast cancer
Patent pending in EU, US, CA, JP, BR,



Accurate, easy and fast to implement




A Multi-Billion Market Ready for Disruption

expressTEC  Platform TAM

IVD - Oncology Companion Diagnostics
(CDx)

€8.38 billion by 2030 - 8.7% CAGR



 expressPIK

Total Addressable Market

HR-positive, HER2-negative, metastatic breast cancer


Serviceable Addressable Market

High-income countries

Serviceable Obtainable Market

expressPIK 3 years post-launch

Scalable Technology with positive growth outlook



Gross Revenue of 1st product in 2030

Scalable, Sustainable, and Secure



Revenue Streams

Test kits,
Companion diagnostic
partnerships



Business Scalability

Partnerships with labs
and pharma companies to
expand market reach




IP Strategy

Owners of patent pending:
EU, US, CA, BR, JP
Trademark in EU & US



Market Entry

Breast → Colorectal → Ovarian Cancer
RUO → Diagnostics
Solid Biopsy → Liquid biopsy → Full Platform



Gross Margin ~50%

Breakeven Q1 2029

Based on indicative 1000€/test

Team with +35 years of combined cancer research experience



Ana-Teresa Maia, PhD, EMBA

CEO & co-Founder
Research pioneer and
international projects leader



Joana Xavier, PhD

CTO & co-Founder
Research leader
Computational biology expert



Joaquim Nascimento, MBA

CMO

Expert healthcare market
strategist and project manager



André Duarte, MSc

Research Scientist

Wet and dry-lab expertise in
Oncobiology and Pharmacy



Frederico Côrte-Real, BA

Advisory CFO


Finance Business Partner and
CorpDev in Portuguese Unicorn



Investment

Raising €1M Seed Funding

- Launching expressPIK as RUO
- Initiate IVDR regulatory process




Funding To-Date:

- €100,000
Portugal Ventures Investment
- €287,000
European Regional Development Fund
- €160,000
Awards

Starting in 2025:

- €620,000
European Regional Development Fund



expressTEC

accurate personalised cancer treatment



expresstec.pt



atmaia@expresstec.pt

expressTEC 



Santander X



expressPIK tests closer to the therapy target

expressTEC 









 expressPIK[®]



Therascreen PIK3CA[®]



FoundationOne[®]

	expressTEC   expressPIK [®]	 Therascreen PIK3CA [®]	 FoundationOne [®]	
Testing Material	RNA	DNA	DNA	
Therapy Efficacy	+10-20%			Unique features
Prognosis Indication				
No hidden costs				
Effortless setup in labs				
Technology	PCR	PCR	NGS	Competitive features
Fast report	1 day	1 day	1-2 weeks	
Price	€ 1.000	€ 232	€ 5.500	